-
Hard Copy
-
Electronic
-
1 - 5 Users
-
1 - 10 Users
-
1 - 15 Users
Colorectal Cancer (CRC) Therapeutics - Global Strategic Business Report
Global Industry Analysts, Inc, October 2006, Pages: 387
This report analyzes the worldwide markets for Colorectal Cancer Therapeutics in US$ Million. The major product segments analyzed are Cytotoxic Therapies (5-FU (Fluorouracil), Camptosar (Irinotecan), Eloxatin (Oxaliplatin), and Xeloda (Capecitabine), Targeted Therapies (Avastin (bevacizumab), and Erbitux (cetuximab). The report provides separate comprehensive analytics for the United States and Rest of World. Annual forecasts are provided for the period of 2001 through 2010. The report profiles 69 companies including many key and niche players worldwide such as Amgen Inc., Bristol-Myers Squibb, F.Hoffmann-La Roche Ltd., Genentech, Inc., Imclone Systems Inc., Novartis AG, Oxford Biomedica, Pfizer Inc., Sanofi-Aventis, and Schering AG. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks.
For information on site licence pricing please click on "Enquire before buying"
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability And Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-2
Product Definitions And Scope Of Study I-3
Cytotoxic Therapies I-3
Targeted Therapies I-3
II. EXECUTIVE SUMMARY
1. Industry Overview II-1
A Curtain Raiser II-1
Table 1: New Cases of Colorectal Cancer Diagnosed in the US
for 2003-2006 (includes corresponding Graph/Chart) II-1
Table 2: Mortality Due to Colorectal Cancer in North America
(2000-2003)-Breakdown by Region-United States, Canada and
Mexico (includes corresponding Graph/Chart) II-2
Table 3: Mortality Due to Colorectal Cancer in Latin America
(2000-2003)-Breakdown by Region-Brazil, Argentina, Venezuela,
Peru, and Chile (includes corresponding Graph/Chart) II-2
Table 4: Mortality Due to Colorectal Cancer in Asia-Pacific
(2000-2003)-Breakdown by Region-China, Japan, India,
Indonesia, Philippines, Australia, Thailand, South Korea,
Malaysia, Hong Kong, New Zealand, Singapore and Taiwan
(includes corresponding Graph/Chart) II-3
Table 5: Mortality Due to Colorectal Cancer in Western Europe
(2000-2003)-Breakdown by Region-Belgium, Austria, Denmark
and Finland (includes corresponding Graph/Chart) II-3
Table 6: Staged Incidence of Cancer in the US by Race/
Ethnicity: (1992-2000) (includes corresponding Graph/Chart) II-4
Why Screening Rate is Low in Colorectal Cancer? II-4
Strategies to Increase Screening Rate II-5
Early Screening & Detection- A Antidotes to Beat the Odds II-5
Test at Home II-5
Breakdown of Colorectal Cancer Cases Based on the Risk
Category II-6
Guidelines for Screening & Surveillance For Early Detection
of Colorectal Cancer II-6
Who is at a Greater Risk of Developing Colorectal Cancer? II-7
Genetic Disposition II-7
Table 7: Selected Risk Factors and their Relative Risk
Percentage in Colorectal Cancer (includes corresponding
Graph/Chart) II-7
Happy Days are Here Again II-8
Table 8: Five Year Disease -Free Survival Rate of Various
Cancers by Type- Colorectal Cancer, Cervical Cancer, Ovarian
Cancer, Breast Cancer, and Malignant Melanoma (includes
corresponding Graph/Chart) II-8
An Insight into Colorectal Cancer Therapeutic Alternatives II-9
2. Market Pulse II-10
Is Huge Cost of Drugs a Major Concern? II-10
Price Comparisons Among Leading Cancer Drugs Currently
Available II-10
Is Cytotoxic Therapy Heading Towards the Sunset? II-10
An Insight into Cytotoxic Drugs Available in the US
Colorectal Cancer Market II-11
Expiry Period of Leading Cytotoxic Drugs- Camptosar,
Eloxatin, and Xeloda II-11
5-FU Struggling to Hold Share II-11
Xeloda on a Rise with Growing Indications II-11
Ongoing Phase III Clinical Trials to Evaluate Efficacy of
Xeloda in Colorectal Cancer II-12
Edotecarin-An Evolving Cytotoxic Therapy II-12
Targeted Therapies-All Set to Stake a Claim Over the Future II-12
Avastin- The Wonder Drug II-13
Table 9: Key Parameters that Promote use of Avastin (includes
corresponding Graph/Chart) II-13
PTK787 (vatalanib) II-13
ABX-EGF II-14
Targeted Therapies Add Value to Treatment Strategies II-14
Panitumumab- A Key Contender to Erbitux II-14
PTK787 v/s Avastin- Serious Warfare II-15
Combination Therapy- Offering a Lucrative Option II-15
A Peek into Standard Combination Therapies in Colorectal
Cancer and their Status II-15
Reoccurrence of Cancer -A Prime Concern II-16
Table 10: Revenues from Adjuvant Colorectal Cancer Therapies
in the US 2004-2007 (In US$ Million) (includes corresponding
Graph/Chart) II-16
Table 11: Number of Colorectal Cancer Patients in Adjuvant
Settings in the US: 2001-2007 (includes corresponding Graph/
Chart) II-16
Adjuvant Therapy in Colon Cancer II-17
Adjuvant Therapy in Rectal Cancer II-17
Colorectal Cancer Drugs in Adjuvant Settings II-17
3. Clinical Trials II-18
Prominent Products Still in Pipeline II-18
A Snapshot of Potential Drugs in the Pipeline II-18
4. Clinical Studies II-20
Adapalene (CD271) Retinoid Agent Induces Apoptosis in Colon
Cancer Cells II-20
Laparoscopic Surgery Vs Open Surgery II-20
Discontinuation of Chemotherapy Drugs Raises the Chances of
Reoccurrence II-20
Colorectal Cancer and Natural Substances II-20
Magnesium II-20
Vitamin D Protects Development of Tumor in Colon II-21
High Intake of Vitamin B Reduces Risk in Women II-21
Diet Rich in Flavonoids Fights Well Against Colorectal Cancer II-21
Colorectal Cancer and Other Medications II-21
NSAIDs Reduce the Risk of Colorectal Cancer II-21
Efficacy of Cancer Vaccine, ALVAC-CEA/B7.1, in Colorectal
Cancer II-21
Insulin Therapy in type 2 Diabetic Patients Increases Risk II-22
5. Product Overview II-23
Colorectal Cancer-An Insight II-23
Colorectal Cancer . What is it .!!! II-23
What are the Symptoms? II-23
Risk Factors II-24
Selected General Risk Factors and their Relative Risk Rate
in Colorectal Cancer II-24
Screening and Treatment II-25
Screening Options II-25
Digital Rectal Examination (DRE) II-25
Fecal Occult Blood Test II-25
Flexible Sigmoidoscopy II-25
Barium Enema II-25
Colonoscopy II-25
Additional Screening Options Of Recent Origin II-25
DNA-based Stool Test II-25
Virtual Colonoscopy II-26
A Comparative Analysis of Various Colorectal Cancer
Screening Options Based on Parameters Such as
Complexity, Risk Element, Potential Effectiveness,
Overall Performance and Significant Limitations II-26
Appropriate Time Frame for Screening and Surveillance of
Colorectal Cancer for Both Women and Men in the Age
Group of 50 or More II-26
Supportive Diagnostic Tests II-27
Diagnosis/Treatment Options II-27
Partial Colectomy II-27
Chemotherapy II-27
Surgery II-27
Radiation Therapy II-27
A Structural Analysis of Available Treatment Options in
Colorectal Cancer II-28
Staging II-28
Colorectal Cancer Therapies-At a Glance II-29
Cytotoxic Therapies II-29
5-FU (Fluorouracil) II-29
Camptosar (Irinotecan) II-29
Eloxatin (Oxaliplatin) II-29
Xeloda (Capecitabine) II-30
Targeted Therapies II-30
Angiogenesis Pathway II-30
Avastin (bevacizumab) II-31
EGF Pathway II-31
Erbitux (cetuximab) II-31
Cell Proliferation/Apoptosis II-32
Immune Response II-32
Cancer Vaccines II-32
Monoclonal Antibodies & their Function II-32
An Insight into the Targeted Therapies II-33
A Synoptic Review of Available Drugs Indicated in
Treating Colorectal Cancer II-33
6. Product Approvals /Launches II-34
Chugai Applies for Quick Approval of Avastin in Japan II-34
Genentech Obtains FDA Approval for Avastin in Combination
Therapy II-34
US FDA Approves Adjuvant Status for Roche’s Oral Xeloda II-34
Antisoma’s AS 1404 and Avastin Combination Therapy Proves
Effective in Colon and Lung Cancer II-35
ImClone Systems and Bristol-Myers Squibb Receive Approval for
Erbitux® Injection II-35
John Hopkins Develops Colorectal Cancer Blood Test Jointly
with Howard Hughes Medical Institute and Indivumed II-35
Genentech Receives FDA Approval for Avastin II-35
Oxford BioMedica Gains Approval for Phase II Trial of TroVax® II-36
Roche’s Xeloda Gets Clearance as First-Line Colorectal Cancer
Treatment II-36
LabCorp Introduces DNA-based Colorectal Cancer Test II-36
7. Recent Industry Activity II-37
Amgen Acquires Abgenix II-37
Chiron Merges with Novartis II-37
Bayer to Acquire Schering AG II-37
Biosite Collaborates with Oxford Genome II-37
Medarex Collaborates with Oxford Genome Sciences II-37
Pharmexa Acquires GemVax II-38
AstraZeneca to Acquire KuDOS Pharmaceuticals II-38
Aphton Corporation Acquires Igeneon II-38
IDM S.A. and Epimmune Merge to Form IDM Pharma II-38
Hybridon Renamed as Idera Pharmaceuticals II-38
Merck KGaA Acquires Rights for Taiho Pharmaceutical’s UFT II-38
Novartis and Schering Co-Promote PTK787/ZK 222584 Cancer Drug II-38
TWTI and Genzyme Genetics Set Up a Marketing Association II-39
Callisto Receives Patent for its Colon Cancer Drug II-39
Amgen and Abgenix Receive FDA Approval for Panitumumab in
Metastatic Colorectal Cancer II-39
ADVENTRX Receives MHRA Approval to Initiate Phase IIb
Clinical Trial II-39
Sanofi Acquires Aventis to Form Sanofi-Aventis II-39
8. Focus on Select Players II-40
Amgen Inc. (USA) II-40
Bristol-Myers Squibb (USA) II-40
F.Hoffmann-La Roche Ltd. (Switzerland) II-40
Genentech, Inc. (USA) II-40
Imclone Systems Inc. (USA) II-41
Novartis AG (Switzerland) II-41
Oxford Biomedica (UK) II-41
Pfizer Inc. (USA) II-41
Sanofi-Aventis (France) II-42
Schering AG (Germany) II-42
9. Global Market Perspective II-43
Table 12: World Recent Past, Current & Future Analysis for
Colorectal Cancer Therapeutics by Geographic Region/Country -
United States and Rest of World Markets Independently
Analyzed with Annual Sales in US$ Million for Years 2001
through 2010 (includes corresponding Graph/Chart) II-43
Table 13: World 10-Year Perspective for Colorectal Cancer
Therapies by Geographic Region/Country
Percentage Breakdown
of Dollar Sales for United States and Rest of World for Years
2001, 2006 and 2010 II-43
Table 14: World Recent Past, Current & Future Analysis for
Cytotoxic Therapies for Colorectal Cancer by Geographic
Region/Country
United States and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2001 through 2010 (includes corresponding Graph/Chart) II-44
Table 15: World 10-Year Perspective for Cytotoxic Therapies
for Colorectal Cancer by Geographic Region/ Country -
Percentage Breakdown of Dollar Sales for United States and
Rest of World for Years 2001, 2006 and 2010 II-44
Table 16: World Recent Past, Current & Future Analysis for
Camptosar in Colorectal Cancer by Geographic Region/ Country -
United States and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) II-45
Table 17: World 10-Year Perspective for Camptosar in
Colorectal Cancer by Geographic Region/ Country
Percentage
Breakdown of Dollar Sales for United States and Rest of World
for Years 2001, 2006 and 2010 II-45
Table 18: World Recent Past, Current & Future Analysis for
Eloxatin in Colorectal Cancer by Geographic Region/ Country -
United States and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2001 through 2010
(includes corresponding Graph/Chart) II-46
Table 19: World 10-Year Perspective for Eloxatin in
Colorectal Cancer by Geographic Region/ Country
Percentage
Breakdown of Dollar Sales for United States and Rest of World
for Years 2001, 2006 and 2010 II-46
Table 20: World Recent Past, Current & Future Analysis for
Xeloda in Colorectal Cancer by Geographic Region/Country -
United States and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2001 through 2010
(includes corresponding graph/chart) II-47
Table 21: World 10-Year Perspective for Xeloda in Colorectal
Cancer by Geographic Region/Country
Percentage Breakdown of
Dollar Sales for United States and Rest of World for Years
2001, 2006 and 2010 II-47
Table 22: World Recent Past, Current & Future Analysis for
Targeted Therapies for Colorectal Cancer by Geographic
Region/Country
United States and Rest of World Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2004 through 2010 (includes corresponding graph/chart) II-48
Table 23: World 6-Year Perspective for Targeted Therapies for
Colorectal Cancer by Geographic Region/Country
Percentage
Breakdown of Dollar Sales for United States and Rest of World
for Years 2004, 2006 and 2010 II-48
Table 24: World Recent Past, Current & Future Analysis for
Avastin in Colorectal Cancer by Geographic Region/ Country -
United States and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2004 through 2010
(includes corresponding graph/chart) II-49
Table 25: World 6-Year Perspective for Avastin in Colorectal
Cancer by Geographic Region/Country
Percentage Breakdown of
Dollar Sales for United States and Rest of World for Years
2004, 2006 and 2010 II-49
Table 26: World Recent Past, Current & Future Analysis for
Erbitux in Colorectal Cancer by Geographic Region/ Country -
United States and Rest of World Markets Independently Analyzed
with Annual Sales in US$ Million for Years 2004 through 2010
(includes corresponding graph/chart) II-50
Table 27: World 6-Year Perspective for Erbitux in Colorectal
Cancer by Geographic Region/Country
Percentage Breakdown of
Dollar Sales for United States and Rest of World for Years
2004, 2006 and 2010 II-50
III. MARKET
1. US III-1
A.Market Analysis III-1
Introduction III-1
Market Accelerators III-1
Market Challenges III-1
Market Inhibitors III-1
Why Cost of Cancer Drugs is Too High in the US? III-1
Free-market Healthcare System- “For” & “Against” III-2
Erbitux- Making a Way Through the Colorectal Cancer Market III-2
Erbitux-A Blockbuster Drug in Third-Line Therapy III-2
Erbitux Enters the Genre of Second-Line Therapies III-3
Who Leads the Pack? III-3
Sanofi-Aventis- The Clear Leader III-3
Table 28: US Colorectal Cancer Market (2004): Percentage
Breakdown of Leading Players-Sanofi-Aventis, Genentech,
Pfizer, ImClone Systems/Bristol Myers-Squibb, Roche, and
Generic Manufacturers-Ranked by Revenue (includes
corresponding Graph/Chart) III-3
Table 29: US Colorectal Cancer Market for Cytotoxic
Therapies (2004): Percentage Breakdown of Leading Players
-Sanofi-Aventis, Pfizer, Roche and Generic Manufacturers-
Ranked by Revenue (includes corresponding Graph/Chart) III-4
Table 30: US Colorectal Cancer Market for Targeted
Therapies (2004): Percentage Breakdown of Leading Players
-Genentech and ImClone Systems/Bristol Myers-Squibb-
Ranked by Revenues III-4
Crucial Statistics III-4
Table 31: Incidence of Colorectal Cancer in the US (2006
)-Breakdown by Stages (includes corresponding Graph/Chart) III-4
Table 32: US Colorectal Cancer Statistics for 2004 & 2003
(includes corresponding Graph/Chart) III-4
Table 33: New Cases of Colorectal Cancer in the US for the
years 2005 & 2006-Breakdown by Cancer Type III-5
Table 34: New Colorectal Cancer Cases in the US in 2004 &
2003-Breakdown by Type & Gender III-5
Product Approvals/Launches III-5
Strategic Developments III-7
Focus on Select Players III-8
B.Market Analytics III-9
Table 35: US Recent Past, Current & Future Analysis For
Colorectal Cancer Therapeutics By Product Segments-
Cytotoxic Therapies (5-Fu, Camptosar, Eloxatin And Xeloda)
And Targeted Therapies (Avastin And Erbitux) Markets
Independently Analyzed With Annual Sales In Us$ Million For
Years 2001 Through 2010 (includes corresponding Graph/
Chart) III-9
Table 36: US 10-Year Perspective For Colorectal Cancer
Therapeutics By Product Segments
Percentage Breakdown Of
Dollar Sales For Cytotoxic Therapies (5-Fu, Camptosar,
Eloxatin And Xeloda) And Targeted Therapies (Avastin And
Erbitux) For Years 2001, 2006 And 2010 (includes
corresponding Graph/Chart) III-10
2. Rest of World III-11
A.Market Analysis III-11
Focus on Select Countries III-11
Canada III-11
Incidence III-11
Vital Statistics III-11
Table 37: Canadian Cancer Market (2005): Percentage
Breakdown of New Cancer Cases Among Men (includes
corresponding Graph/Chart) III-11
Table 38: Canadian Cancer Market (2005): Percentage
Breakdown of Cancer Mortality Among Men (includes
corresponding Graph/Chart) III-11
Table 39: Canadian Cancer Market (2005): Percentage
Breakdown of New Cancer Cases Among Women (includes
corresponding Graph/Chart) III-11
Table 40: Canadian Cancer Market (2005): Percentage
Breakdown of Cancer Mortality Among Women (includes
corresponding Graph/Chart) III-12
Table 41: New Colorectal Cancer Cases in Canada in 2005-
By Gender III-12
Table 42: New Colorectal Cancer Cases in Canada in 2005-
Breakdown By Age Group (includes corresponding Graph/
Chart) III-12
Table 43: Colorectal Cancer Mortality Statistics in
Canada in 2005-Ranked By Gender III-12
Table 44: Colorectal Cancer Mortality Statistics in
Canada in 2005-Breakdown By Age Group (includes
corresponding Graph/Chart) III-13
Table 45: Incidence of Colorectal Cancer Among Men in
Canada-By Region: 2005 (includes corresponding Graph/
Chart) III-13
Table 46: Incidence of Colorectal Cancer Among Women in
Canada-By Region: 2005 (includes corresponding Graph/
Chart) III-13
Finland III-14
Overview III-14
Active Screening Programs- A Mission to Fight Against Cancer III-14
Product Approvals III-14
Strategic Developments III-15
Focus on Select Players III-17
B.Market Analytics III-19
Table 47: Rest of World Recent Past, Current & Future
Analysis for Colorectal Cancer Therapeutics by Product
Segments- Cytotoxic Therapies (Camptosar, Eloxatin and
Xeloda) and Targeted Therapies (Avastin and Erbitux) Markets
Independently Analyzed with Annual Sales in US$ Million for
Years 2001 through 2010 (includes corresponding Graph/
Chart) III-19
Table 48: Rest of World 10-Year Perspective for Colorectal
Cancer Therapeutics by Product Segments
Percentage
Breakdown of Dollar Sales for Cytotoxic Therapies
(Camptosar, Eloxatin and Xeloda) and Targeted Therapies
(Avastin and Erbitux) for Years 2001, 2006 and 2010
(includes corresponding Graph/Chart) III-19
IV. COMPETITION
1. Abbott Laboratories (USA) IV-1
Table 49: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-3
Table 50: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-3
Table 51: Half Yearly Sales Analysis by Business
Segment: 2005-2006 (H1) (In US$ million) IV-4
Table 52: Annual Sales Analysis: 2003-2005 (In US$
million) IV-4
Table 53: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-4
Table 54: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ million) IV-4
Table 55: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-5
2. Adherex Technologies, Inc. (USA) IV-14
3. Adventrx Pharmaceuticals, Inc. (USA) IV-16
4. Amgen, Inc. (USA) IV-18
Table 56: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-19
Table 57: Half Yearly Sales Analysis by Segment: 2005-
2006 (H1) (In US$ million) IV-19
Table 58: Annual Sales Analysis: 2004-2005 (In US$
million) IV-19
Table 59: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-19
Table 60: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-19
5. AnorMed, Inc. (Canada) IV-22
Table 61: Annual Sales Analysis: 2004-2006 (In Can$
million) IV-22
6. Antigenics, Inc. (USA) IV-24
Table 62: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-25
Table 63: Half Yearly Sales Analysis by Quarter: 2005-
2006 (H1) (In US$ million) IV-25
Table 64: Annual Sales Analysis: 2003-2005 (In US$
million) IV-25
7. Aphton Corporation (USA) IV-28
8. Arius Research, Inc. (Canada) IV-31
Table 65: Annual Sales Analysis: 2004-2005 (In Can$
million) IV-31
9. Astellas Pharma US, Inc. (USA) IV-33
10. Astrazeneca PLC (UK) IV-35
Table 66: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-37
Table 67: Half Yearly Sales Analysis by Quarter: 2005-
2006 (H1) (In US$ million) IV-37
Table 68: Half Yearly Sales Analysis by Geographic
Region: 2005-2006 (H1) (In US$ million) IV-38
Table 69: Annual Sales Analysis: 2003-2005 (In US$
million) IV-38
Table 70: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-38
Table 71: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-38
11. Avastin (USA) IV-47
12. AVI Biopharma, Inc. (USA) IV-48
Table 72: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ thousands) IV-49
Table 73: Half Yearly Sales Analysis by Quarter: 2005-
2006 (In US$ thousands) IV-49
Table 74: Annual Sales Analysis: 2003-2005 (In US$
thousands) IV-49
Table 75: Quarterly Sales Analysis: 2004-2005 (In US$
thousands) IV-49
13. Bayer HealthCare AG (Germany) IV-52
Table 76: Annual Sales Analysis: 2004-2005 (In €
million) IV-54
Table 77: Annual Sales Analysis by Business Segment:
2004-2005 (In € million) IV-54
Table 78: Annual Sales Analysis by Geographic Region:
2004-2005 (In € million) IV-54
14. Biomira, Inc. (Canada) IV-58
15. Biosite, Inc. (USA) IV-59
Table 79: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-60
Table 80: Annual Sales Analysis: 2004-2005 (In US$
million) IV-60
Table 81: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-60
16. BioStratum, Inc. (USA) IV-64
17. Boehringer Ingelheim GmbH (Germany) IV-65
Boehringer Ingelheim Corporation (USA) IV-69
18. Bristol-Myers Squibb Company (USA) IV-71
Table 82: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ billion) IV-73
Table 83: Half Yearly Sales Analysis by Quarter: 2005-
2006 (H1) (In US$ billion) IV-73
Table 84: Half Yearly Sales Analysis by Business
Segment: 2005-2006 (H1) (In US$ billion) IV-73
Table 85: Annual Sales Analysis: 2003-2005 (In US$
billion) IV-73
Table 86: Annual Sales Analysis by Quarter: 2004-2005
(In US$ billion) IV-73
Table 87: Annual Sales Analysis by Business Segment:
2004-2005 (In US$ billion) IV-74
Table 88: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ billion) IV-74
19. Callisto Pharmaceuticals, Inc. (USA) IV-79
20. ChemGenex Pharmaceuticals Ltd. (Australia) IV-83
Table 89: Annual Sales Analysis: 2004-2005 (In US$
thousands) IV-84
21. Dendreon Corporation (USA) IV-86
Table 90: First Quarter Sales Analysis: 2005-2006 (In
US$ million) IV-86
Table 91: Annual Sales Analysis: 2004-2005 (In US$
million) IV-86
Table 92: Quarterly Sales Analysis: 2004-2005 (In US$
million) IV-87
Eisai, Inc. (USA) IV-88
22. Eli Lilly & Company (USA) IV-90
Table 93: Annual Sales Analysis: 2003-2005 (In US$
million) IV-92
23. F. Hoffmann-La Roche Ltd. (Switzerland) IV-97
Table 94: First Quarter Sales Analysis: 2005-2006 (In
CHF billion) IV-98
Table 95: First Quarter Sales Analysis by Segment:
2005-2006 (In CHF billion) IV-98
Table 96: Annual Sales Analysis: 2003-2005 (In CHF
billion) IV-98
Roche Laboratories, Inc. (USA) IV-101
Chugai Pharmaceutical Co., Ltd. (Japan) IV-101
Table 97: First Quarter Sales Analysis: 2005-2006 (In ¥
million) IV-102
Table 98: Annual Sales Analysis: 2004-2005 (In ¥
million) IV-102
24. Gemin X Biotechnologies, Inc. (Canada) IV-105
25. Genentech, Inc. (USA) IV-106
Table 99: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-108
Table 100: Annual Sales Analysis: 2004-2005 (In US$
million) IV-108
Table 101: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-108
26. Genvec, Inc. (USA) IV-113
Table 102: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-114
Table 103: Annual Sales Analysis: 2004-2005 (In US$
million) IV-114
27. Genzyme Corporation (USA) IV-119
Table 104: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-122
Table 105: Half Yearly Sales Analysis by Quarter: 2005
-2006 (H1) (In US$ million) IV-122
Table 106: Half Yearly Sales Analysis by Segment: 2005
-2006 (H1) (In US$ million) IV-123
Table 107: Annual Sales Analysis: 2004-2005 (In US$
million) IV-123
Table 108: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-123
Table 109: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-123
Table 110: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ billion) IV-124
28. Glaxosmithkline PLC (UK) IV-129
Table 111: Half Yearly Sales Analysis: 2005-2006 (H1)
(In £ million) IV-130
Table 112: Half Yearly Sales Analysis by Segment: 2005
-2006 (H1) (In £ million) IV-130
Table 113: Annual Sales Analysis: 2004-2005 (In £
million) IV-130
Table 114: Annual Sales Analysis by Segment: 2004-2005
(In £ million) IV-130
GlaxoSmithKline, Inc. (USA) IV-139
29. Glycogenesys, Inc. (USA) IV-142
30. Idera Pharmaceuticals, Inc. (USA) IV-143
31. IDM Pharma, Inc. (USA) IV-144
Table 115: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-144
Table 116: Half Yearly Sales Analysis by Quarter: 2005
-2006 (H1) (In US$ million) IV-144
Table 117: Annual Sales Analysis: 2004-2005 (In US$
million) IV-145
32. ImClone Systems, Inc. (USA) IV-146
Table 118: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-147
Table 119: Annual Sales Analysis: 2003-2005 (In US$
million) IV-147
Table 120: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-148
33. Immunomedics, Inc. (USA) IV-150
Table 121: Nine Months Sales Analysis: 2005-2006 (Nine
Months Ended, March) (In US$ million) IV-151
Table 122: Nine Months Sales Analysis by Geographic
Region: 2005-2006 (Nine Months Ended, March) (In US$
million) IV-151
Table 123: Annual Sales Analysis: 2004-2005 (In US$
million) IV-151
Table 124: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-151
34. Indivumed GmbH (Germany) IV-153
35. Intracel (USA) IV-154
36. Introgen Therapeutics, Inc. (USA) IV-155
Table 125: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-156
Table 126: Annual Sales Analysis: 2003-2005 (In US$
million) IV-156
37. Ivax Corporation (USA) IV-159
Table 127: Nine Months Sales Analysis: 2004-2005 (Nine
Months Ended, September) (In US$ billion) IV-162
Table 128: Nine Months Sales Analysis by Quarter: 2004
-2005 (Nine Months Ended, September) (In US$ billion) IV-162
Table 129: Nine Months Sales Analysis by Product: 2004
-2005 (Nine Months Ended, September) (In US$ billion) IV-162
Table 130: Nine Months Sales Analysis by Geographic
Region: 2004-2005 (Nine Months Ended, September) (In
US$ billion) IV-162
38. Johnson & Johnson Pharmaceutical Research & Development
LLC (USA) IV-169
39. Lorus Therapeutics (Canada) IV-171
40. Medarex, Inc. (USA) IV-174
Table 131: First Quarter Sales Analysis: 2005-2006 (Q1)
(In US$ million) IV-175
Table 132: Annual Sales Analysis: 2003-2005 (In US$
million) IV-175
Table 133: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-175
41. MediGene AG (Germany) IV-179
Table 134: Half Yearly Sales Analysis: 2005-2006 (H1)
(In € million) IV-179
42. Medimmune, Inc. (USA) IV-181
Table 135: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-182
Table 136: Half Yearly Sales Analysis by Quarter: 2005
-2006 (H1) (In US$ million) IV-182
Table 137: Half Yearly Sales Analysis by Operation:
2006-2005 (In US$ IV-183
Table 138: Annual Sales Analysis: 2003-2005 (In US$
million) IV-183
Table 139: Annual Sales Analysis by Operation: 2004-
2005 (In US$ million) IV-183
Table 140: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-183
43. Merck & Co., Inc. (USA) IV-186
Table 141: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-187
Table 142: Half Yearly Sales Analysis by Quarter: 2005
-2006 (H1) (In US$ million) IV-187
Table 143: Half Yearly Sales Analysis by Product: 2005
-2006 (H1) (In US$ million) IV-187
Table 144: Annual Sales Analysis: 2003-2005 (In US$
million) IV-188
Table 145: Annual Sales Analysis by Product: 2004-2005
(In US$ million) IV-188
Table 146: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-188
44. Merck KGaA (Germany) IV-193
Table 147: Annual Sales Analysis: 2004-2005 (In €
million) IV-195
Table 148: Annual Sales Analysis Segment: 2004-2005 (In
€ million) IV-195
45. Millennium Pharmaceuticals, Inc. (USA) IV-199
Table 149: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-199
Table 150: Annual Sales Analysis: 2004-2005 (In US$
million) IV-199
Table 151: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-200
46. Myriad Genetics, Inc. (USA) IV-202
Table 152: Nine Months Sales Analysis: 2005-2006 (Nine
Months Ended, March) (In US$ million) IV-203
Table 153: Nine Months Sales Analysis by Quarter: 2005
-2006 (Nine Months Ended, March) (In US$ million) IV-203
Table 154: Nine Months Sales Analysis by Segment: 2005
-2006 (Nine Months Ended, March) (In US$ million) IV-203
Table 155: Annual Sales Analysis: 2004-2005 (In US$
million) IV-203
Table 156: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-203
Table 157: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-204
47. Novartis AG (Switzerland) IV-205
Table 158: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-208
Table 159: Half Yearly Sales Analysis by Segment: 2005
-2006 (H1) (In US$ million) IV-208
Table 160: Annual Sales Analysis: 2003-2005 (In US$
million) IV-209
Table 161: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-209
Table 162: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-209
Chiron Corporation (USA) IV-217
Table 163: Annual Sales Analysis: 2003-2005 (In US$
million) IV-219
Table 164: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) IV-219
Table 165: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-220
Table 166: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-220
Novartis Pharmaceuticals Corporation (USA) IV-224
48. Onyx Pharmaceuticals, Inc. (USA) IV-229
Table 167: Annual Sales Analysis: 2004-2005 (In US$
million) IV-230
49. Ortho Biotech Products LP (USA) IV-231
50. OSI Pharmaceuticals (USA) IV-233
Table 168: Half Yearly Sales Analysis: 2005-2006 (In
US$ million) IV-234
Table 169: Annual Sales Analysis: 2004-2005 (In US$
million) IV-234
51. Oxford Biomedica PLC (UK) IV-237
Table 170: Annual Sales Analysis: 2004-2005 (In £
million) IV-237
52. Oxford Genome Sciences (U.K.) Ltd. (UK) IV-241
53. Oxigene, Inc. (USA) IV-243
54. Pfizer, Inc. (USA) IV-245
Table 171: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ billion) IV-247
Table 172: Half Yearly Sales Analysis by Segment: 2005
-2006 (H1) (In US$ billion) IV-247
Table 173: Half Yearly Sales Analysis by Geographic
Region: 2005-2006 (H1) (In US$ billion) IV-248
Table 174: Annual Sales Analysis: 2003-2005 (In US$
billion) IV-248
55. Pharmexa A/S (Denmark) IV-252
Table 175: Half Yearly Sales Analysis: 2005-2006 (H1)
(In DKK million) IV-252
56. Sanofi-Aventis (France) IV-257
Table 176: Half Yearly Sales Analysis: 2005-2006 (H1)
(In € million) IV-258
Table 177: Half Yearly Sales Analysis by Quarter: 2005
-2006 (H1) (In € million) IV-258
Table 178: Annual Sales Analysis: 2004-2005 (In €
million) IV-258
Table 179: Annual Sales Analysis by Segment: 2004-2005
(In € million) IV-258
Table 180: Annual Sales Analysis by Geographic Region:
2004-2005 (In € million) IV-259
Sanofi-Aventis (USA) IV-264
57. Schering AG (Germany) IV-266
Table 181: First Quarter Sales Analysis: 2005-2006 (In
€ billion) IV-267
Table 182: First Quarter Sales Analysis by Segment:
2005-2006 (In € billion) IV-267
Table 183: First Quarter Sales Analysis by Geographic
Region: 2005-2006 (In € billion) IV-268
Table 184: Annual Sales Analysis: 2003-2005 (In €
billion) IV-268
Table 185: Annual Sales Analysis by Segment: 2004-2005
(In € billion) IV-268
Table 186: Annual Sales Analysis by Geographic Region:
2004-2005 (In € billion) IV-268
Schering-Plough Corporation (USA) IV-273
Table 187: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-274
Table 188: Half Yearly Sales Analysis by Segment: 2005
-2006 (H1) (In US$ million) IV-274
Table 189: Annual Sales Analysis: 2004-2005 (In US$
million) IV-274
Table 190: Annual Sales Analysis by Quarter: 2004-2005
(In US$ million) (Germany)) IV-274
Table 191: Annual Sales Analysis by Segment: 2004-2005
(In US$ million) IV-275
Table 192: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-275
58. Supergen, Inc. (USA) IV-278
Table 193: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-279
Table 194: Half Yearly Sales Analysis by Quarter: 2005
-2006 (H1) (In US$ million) IV-279
Table 195: Annual Sales Analysis: 2004-2005 (In US$
million) IV-279
59. Telik, Inc. (USA) IV-281
60. Therion Biologics Corporation (USA) IV-283
61. Third Wave Technologies, Inc. (USA) IV-284
Table 196: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-285
Table 197: Annual Sales Analysis: 2004-2005 (In US$
million) IV-285
62. Titan Pharmaceuticals, Inc. (USA) IV-287
Table 198: Annual Sales Analysis: 2004-2005 (In US$
million) IV-287
63. Topotarget A/S (Denmark) IV-289
Table 199: Annual Sales Analysis: 2004-2005 (In DKK
million) IV-289
64. Transgene SA (France) IV-291
Table 200: Half Yearly Sales Analysis: 2005-2006 (H1)
(In € million) IV-291
Table 201: Annual Sales Analysis: 2004-2005 (In €
million) IV-291
65. Viventia Biotech, Inc. (Canada) IV-293
66. Wyeth (USA) IV-294
Table 202: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ billion) IV-296
Table 203: Half Yearly Sales Analysis by Segment: 2006
-2005 (H1) (In US$ billion) IV-296
Table 204: Annual Sales Analysis: 2004-2005 (In US$
billion) IV-296
Table 205: Annual Sales Analysis by Segment: 2004-2005
(In US$ billion) IV-296
Table 206: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ billion) IV-296
67. Xoma (US) LLC (USA) IV-301
Table 207: Half Yearly Sales Analysis: 2005-2006 (H1)
(In US$ million) IV-301
Table 208: Annual Sales Analysis: 2004-2005 (In US$
million) IV-302
Table 209: Annual Sales Analysis by Geographic Region:
2004-2005 (In US$ million) IV-302
68. YM Biosciences, Inc. (Canada) IV-305
Table 210: Nine Months Sales Analysis: 2005-2006 (Nine
Months Ended, March) (In Can$ million) IV-305
Table 211: Annual Sales Analysis: 2004-2005 (In Can$
million) IV-305
The Companies mentioned inside this report include:
- Abbott Laboratories (USA)
- Adherex Technologies, Inc (USA)
- Adventrx Pharmaceuticals, Inc (USA)
- Amgen, Inc (USA)
- AnorMed, Inc (Canada)
- Antigenics, Inc (USA)
- Aphton Corporation (USA)
- Arius Research, Inc (Canada)
- Astellas Pharma US, Inc (USA)
- Astrazeneca PLC (UK)
- Avastin (USA)
- AVI Biopharma, Inc (USA)
- Bayer HealthCare AG (Germany)
- Biomira, Inc (Canada)
- Biosite, Inc (USA)
- BioStratum, Inc (USA)
- Boehringer Ingelheim GmbH (Germany)
- Boehringer Ingelheim Corporation (USA)
- Bristol-Myers Squibb Company (USA)
- Callisto Pharmaceuticals, Inc (USA)
- ChemGenex Pharmaceuticals Ltd (Australia)
- Dendreon Corporation (USA)
- Eisai, Inc (USA)
- Eli Lilly & Company (USA)
- F Hoffmann-La Roche Ltd (Switzerland)
- Roche Laboratories, Inc (USA)
- Chugai Pharmaceutical Co, Ltd (Japan)
- Gemin X Biotechnologies, Inc (Canada)
- Genentech, Inc (USA)
- Genvec, Inc (USA)
- Genzyme Corporation (USA)
- Glaxosmithkline PLC (UK)
- GlaxoSmithKline, Inc (USA)
- Glycogenesys, Inc (USA)
- Idera Pharmaceuticals, Inc (USA)
- IDM Pharma, Inc (USA)
- ImClone Systems, Inc (USA)
- Immunomedics, Inc (USA)
- Indivumed GmbH (Germany)
- Intracel (USA)
- Introgen Therapeutics, Inc (USA)
- Ivax Corporation (USA)
- Johnson & Johnson Pharmaceutical Research & Development LLC (USA)
- Lorus Therapeutics (Canada)
- Medarex, Inc (USA)
- MediGene AG (Germany)
- Medimmune, Inc (USA)
- Merck & Co, Inc (USA)
- Merck KGaA (Germany)
- Millennium Pharmaceuticals, Inc (USA)
- Myriad Genetics, Inc (USA)
- Novartis AG (Switzerland)
- Chiron Corporation (USA)
- Novartis Pharmaceuticals Corporation (USA)
- Onyx Pharmaceuticals, Inc (USA)
- Ortho Biotech Products LP (USA)
- OSI Pharmaceuticals (USA)
- Oxford Biomedica PLC (UK)
- Oxford Genome Sciences (UK) Ltd (UK)
- Oxigene, Inc (USA)
- Pfizer, Inc (USA)
- Pharmexa A/S (Denmark)
- Sanofi-Aventis (France)
- Sanofi-Aventis (USA)
- Schering AG (Germany)
- Schering-Plough Corporation (USA)
- Supergen, Inc (USA)
- Telik, Inc (USA)
- Therion Biologics Corporation (USA)
- Third Wave Technologies, Inc (USA)
- Titan Pharmaceuticals, Inc (USA)
- Topotarget A/S (Denmark)
- Transgene SA (France)
- Viventia Biotech, Inc (Canada)
- Wyeth (USA)
- Xoma (US) LLC (USA)
- YM Biosciences, Inc (Canada)
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
